PT - JOURNAL ARTICLE AU - Domenico, Laura Di AU - Goldberg, Yair AU - Colizza, Vittoria TI - Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden AID - 10.1101/2024.03.08.24303201 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.08.24303201 4099 - http://medrxiv.org/content/early/2024/03/10/2024.03.08.24303201.short 4100 - http://medrxiv.org/content/early/2024/03/10/2024.03.08.24303201.full AB - As public health policies shifted in 2023 from emergency response to long-term COVID-19 disease management, immunization programs started to face the challenge of formulating routine booster campaigns in a still highly uncertain seasonal behavior of the COVID-19 epidemic. Mathematical models assessing past booster campaigns and integrating knowledge on waning of immunity can help better inform current and future vaccination programs. Focusing on the first booster campaign in the 2021/2022 winter in France, we used a multi-strain age-stratified transmission model to assess the effectiveness of the observed booster vaccination in controlling the succession of Delta, Omicron BA.1 and BA.2 waves. We explored counterfactual scenarios altering the eligibility criteria and inter-dose delay. Our study showed that the success of the immunization program in curtailing the Omicron BA.1 and BA.2 waves was largely dependent on the inclusion of adults among the eligible groups, and was highly sensitive to the inter-dose delay, which was changed over time. Shortening or prolonging this delay, even by only one month, would have required substantial social distancing interventions to curtail the hospitalization peak. Also, the time window for adjusting the delay was very short. Our findings highlight the importance of readiness and adaptation in the formulation of routine booster campaign in the current level of epidemiological uncertainty.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by: Agence Nationale de la Recherche project DATAREDUX (ANR-19-CE46-0008-03) to VC; ANRS - Maladies Infectieuses Emergentes project EMERGEN (ANRS0151) to VC; EU Horizon 2020 grant MOOD (H2020-874850), Horizon Europe grant ESCAPE (101095619) to VC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available online at cited references.